Moderna (MRNA) Net Cash Flow Growth (3y) (2021 - 2026)
Moderna (MRNA) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Moderna | 22.28 Bn | 17.07 Bn | -566.00 Mn | -68.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.96% |
| Dec 31, 2025 | 102.57% |
| Sep 30, 2025 | -43.40% |
| Jun 30, 2025 | 45.82% |
| Mar 31, 2025 | 44.79% |
| Dec 31, 2024 | -39.83% |
| Sep 30, 2024 | -150.59% |
| Jun 30, 2024 | 36.45% |
| Mar 31, 2024 | -32.08% |
| Dec 31, 2023 | -26.46% |
| Sep 30, 2023 | -50.29% |
| Jun 30, 2023 | -35.89% |
| Mar 31, 2023 | 16.08% |
| Dec 31, 2022 | 40.87% |
| Sep 30, 2022 | 91.87% |
| Jun 30, 2022 | -83.62% |
| Mar 31, 2022 | -126.10% |
| Dec 31, 2021 | 38.30% |
| Sep 30, 2021 | -58.80% |
| Jun 30, 2021 | 47.21% |